Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II – III invasive breast cancer: the OOTR-N001 study

By Chow Louis WC   Tung Stewart Y   Ng Ting-Ying   Im Seock-Ah   Lee Min-Hyuk   Yip Adrian YS   Toi Masakazu   Glück Stefan  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 3, 2013-03 ,pp. : 299-307

Informa Healthcare

Access to resources Recommend Favorite

Paclitaxel: As Adjuvant or Neoadjuvant Therapy in Early Breast Cancer

By Dene Simpson   Greg L. Plosker  

Drugs, Vol. 64, Iss. 16, 2004-01 ,pp. : 1839-1847

Adis International

Access to resources Recommend Favorite

Paclitaxel and docetaxel in the treatment of breast cancer

By Saloustros Emmanouel   Mavroudis Dimitris   Georgoulias Vassilis  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 15, 2008-10 ,pp. : 2603-2616

Informa Healthcare

Access to resources Recommend Favorite

Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study

By Boér Katalin  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 681-687

Springer Publishing Company

Access to resources Recommend Favorite

Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer

By Heys Steven D   Sarkar Tarun   Hutcheon Andrew W  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 10, 2004-10 ,pp. : 2147-2157

Informa Healthcare

Access to resources Recommend Favorite